1. Immunology/Inflammation Anti-infection
  2. Interleukin Related Parasite Fungal
  3. Anti-Mouse IL-10R/CD210 Antibody (1B1.3A)

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) 

目录号: HY-P990228 纯度: 95.00%
COA 技术支持

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) 是一种源自大鼠的 IgG1 κ 型抗体抑制剂,靶向小鼠 IL-10R/CD210。Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) 可阻断 IL-10R 信号传导。Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) 可用于癌症、感染和代谢性疾病的研究,如糖尿病和疟疾。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A)

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
1 mg ¥900
In-stock
5 mg ¥3600
In-stock
10 mg 现货 询价
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse IL-10R/CD210. Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) blocks IL-10R signaling. Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) can be used for the researches of cancer, infection and metabolic disease, such as diabetes and malaria[1][2][3][4][5].

同型

Rat IgG1 kappa

推荐同型对照抗体
反应种属

Mouse

IC50 & Target

IL-10R/CD210

体外研究
(In Vitro)

抗体框架具有稳定性、特异性和适应性,同时具有结合抗原和内源免疫受体。 单克隆抗体具有几种衍生物,包括双特异性抗体、抗体-药物缀合物和抗体片段,在免疫学和肿瘤学等领域具有显著效果。 设计抑制性抗体时,需要注意包括抗原特异性可变区的鉴定、表达系统的选择、多特异性形式的使用以及基于片段化、寡聚化或与其他功能部分缀合的抗体衍生物[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) (0.5 mg/dose,腹腔注射,早期治疗在第 3、6、9 天给药 3 次,晚期治疗在第 15、18、21 天给药) 可促进肺新型隐球菌感染模型小鼠中的真菌清除[1]
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) (感染前 1 天给予 0.3 mg/mouse,感染后第 1、4、6 天给予 0.2 mg/mouse,腹腔注射) 会降低伯氏疟原虫 ANKA 感染模型中小鼠的存活率,并增加实验性脑型疟疾的累积发病率[2]
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) (250 μg,静脉注射,每周两次) 可改善 1 型糖尿病小鼠的毛细血管停滞和认知障碍[3]
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) (1.5 mg,腹腔注射,单剂量) 可降低野生型 B6 小鼠肺驻留 T 细胞上的 CD103 表达和 TGF-β1 水平[4]
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) (肿瘤细胞注射当天给予 500 μg,之后每周两次,每次 300 μg,腹腔注射) 在同基因移植模型小鼠中减轻了淋巴瘤负荷,并降低了瘤内调节性 T 细胞的频率[5]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Pulmonary C. neoformans infected mice models[1]
Dosage: 0.5 mg/dose
Administration: Intraperitoneally injection, 3 times for early treatment at days 3, 6, 9 and late treatment at days 15, 18, 21
Result: Significantly reduced pulmonary fungal CFU.
Reduced fungal clearance.
Increased lung leukocyte accumulation and total numbers of CD4+ T cells and Th17 cells.
Increased the total numbers of B cells with late treatment.
Increased IFN-γ levels.
Increased the activation of lung dendritic cells and macrophages.
Reduced central nervous system dissemination.
Animal Model: P. berghei ANKA infected mice models[2]
Dosage: 0.3 mg/mouse at 1 day before infection and 0.2 mg/mouse at days 1, 4, 6 postinfection
Administration: Intraperitoneally injection
Result: Reduced survival rate and parasitemia values and increased cumulative experimental cerebral malaria incidence and CD8+ T cells.
Significantly elevated generalized parasite biomass and the numbers of brain petechial hemorrhages.
Increased IFN-γ and IL-10 levels.
Increased proportions of splenic CD4+ and CD8+ T cells expressing CD62L- and CD11a+and producing IFN-γ.
Animal Model: Type 1 diabetic mice models[3]
Dosage: 250 μg
Administration: Intravenously injection, twice a week
Result: Had significantly lower density of obstructed capillaries in the forebrain or across different brain regions.
Decreased stalling rates, and increases capillary flux and capillary width.
Helped to partially normalize CBF responses and improved cognitive function.
Upregulated gene pathways involved in the regulation of reactive oxygen species and energy metabolism, and downregulated gene pathways that regulate cellular adhesion, platelet activation and atherosclerosis.
Animal Model: Wild-type B6 mice[4]
Dosage: 1.5 mg
Administration: Intraperitoneally injection
Result: Reduced CD103 expression on lung-resident T cells.
Reduced TGF-β1 levels.
Animal Model: Myc-expressing lymphoma tumor mice models[5]
Dosage: 500 μg at day 0 and 300 μg twice a week after tumor cell injection
Administration: Intraperitoneally injection
Result: Strongly reduced lymph node weights and the frequencies of CD19+ CD45int tumor B-cells.
Increased the lymph node frequencies of TCRα/β+ T-cells, equally affecting CD4+ and CD8+ T-cell population.
Increased TNF-α-producing and decreased FoxP3+ regulatory T-cells.
基因 ID

16154  [NCBI]

Accession
应用

ELISA, FACS, Functional assay, Research in vivo

偶联物

Unconjugated

复溶方法

The product can be reconstituted/diluted with sterile PBS or saline.

分子量

150 kDa

性状

液体

颜色

Colorless to light yellow

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料

纯度: 95.00%

参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A)
目录号:
HY-P990228
需求量: